RESULTS OF IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA AND NODULES WITH HIGH-GRADE DYSPLASIA IN PATIENTS WITH CIRRHOSIS

ABSTRACT BACKGROUND: Hepatocellular carcinoma (HCC) is the most frequent primary cancer of the liver and cirrhosis is considered a pre-malignant disease. In this context, the evolutionary sequence from low grade dysplastic nodule and high grade dysplastic nodule (HGDN) to early HCC and advanced HCC has been studied. The differential diagnosis between HGDN and early HCC is still a challenge, especially in needle biopsies OBJECTIVE: To evaluate an immunohistochemistry panel to differentiate dysplastic nodules and HCC. METHODS: Patients with cirrhosis who underwent surgical resection or liver transplantation were included. The sensitivity, specificity and accuracy for the diagnosis of neoplasia were analyzed by evaluating five markers: heat shock protein 70, glypican 3, glutamine synthetase, clathrin heavy chain and beta-catenin. P≤0.05 was considered statistically significant. RESULTS: One hundred and fifty-six nodules were included; of these, 57 were HCC, 14 HGDN, 18 low grade dysplastic nodules and 67 regenerative macronodules. Sensitivity of HCC diagnosis was 64.9% for glypican 3 and 77.2% for glutamine syntetase, while specificity was 96.0% and 96.0% respectively. When the panel of four markers was considered (excluding beta catenin), the specificity ranged from 87.9% for one positive marker to 100% for at least three markers. The best accuracy for HCC diagnosis was obtained with at least two positive markers, which was associated with a sensitivity of 82.5% and specificity of 99%. CONCLUSION: Differential diagnosis of dysplastic nodules and HCC by morphological criteria can be challenging. Immunomarkers are useful and should be used for the differential diagnosis between HCC and HGDN.

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Background. Circulating microRNA-122 (miR-122) has been recognized as a marker of hepatocellular carcinoma (HCC). The current meta-analysis was performed to quantitatively evaluate the diagnostic performance of circulating miR-122 for HCC. Methods. Related studies that evaluated the diagnostic performance of circulating miR-122 determined from pathophysiological examination for HCC were obtained by systematic searches of the PubMed and Embase databases. A randomized fixed effects model was applied according to the heterogeneity among studies. The pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated to evaluate the diagnostic accuracy. Publication bias was detected by Deeks’ funnel plot asymmetry test. Results. Thirteen studies providing data for 920 HCC patients and 1217 controls were included in the meta-analysis. The pooled sensitivities, specificities, and AUCs of serum miR-122 were 0.76, 0.75, and 0.82, respectively, for discriminating HCC patients from overall controls; 0.85, 0.83, and 0.91, respectively, for discriminating HCC patients from healthy controls; 0.79, 0.82, and 0.87, respectively, for discriminating HCC from HBV or HCV infection; and 0.65, 0.75, and 0.74, respectively, for discriminating HCC from liver cirrhosis or dysplastic nodule formation. No significant publication bias was detected. Conclusions. Serum miR-122 confers moderate efficacy for discriminating HCC patients from healthy controls or patients with HBV or HCV infection, but not for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation.

Triple-phase multidetector computed tomography:an evaluation of hepatic space occupying lesion in cirrhotic patients

Hepatocellular carcinoma (HCC) is a common tumor with an incidence of 1 - 6 % among cirrhotic patients. Dysplastic nodule often occurs within regenerative cirrhotic nodules. They can show low or high grade dysplasia. MRI best differentiates this iso-or hypo intense lesion from hyper intense HCC. The current study was designed to assess the usefulness of Triple-phase multiphasic multidetector computed tomography (MDCT) in evaluation of hepatic space occupying lesion in cirrhotic patients.This cross sectional study was carried out in Radiology and Imaging department in collaboration with Hepatology and Hepatobiliary surgery department, of Bangabandhu Sheikh Mujib Medical University, Dhaka during July 2014 to June 2016. A total of 62 cirrhotic patients with hepatic space occupying lesion were included in this study. MDCT was done in all these patients and they were followed-up from the admission up to post operative tissue diagnosis of hepatic space occupying lesion in respective pathology departments to assess the histopathological correlation. Patients with suspected hepatic space occupying lesion diagnosed by clinical andultrasonography and having high serum α-fetoprotein level were enrolled. The mean age was 50.0±13.6 years with ranged from 25 to 79 years. Male female ratio was 2.3:1.In MDCT, a total of 54 malignant cases were found, out of which 49(79.0%) patients had HCC, 4(6.5%) had metastases and 1(1.6%) had dysplastic nodule. In benign tumor group, 6(9.7%) patients had cirrrhotic nodule, 1(1.6%) had hepatic adenoma and 1(1.6%) had haemangioma. In histopahology, a total 53 malignant cases were found, out of them 48(77.5%) patients had HCC, 3(4.8%) had metastases and 2(3.2%) had dysplastic nodule. Triphasic MDCT in diagnosis of hepatic space occupying lesion in cirrhotic patients revealed a sensitivity of 98.1%, specificity of 77.8%, accuracy 95.2%, positive predictive values 96.3% and negative predictive values 87.5%. While the same diagnostic tool showed a sensitivity95.8%, specificity 78.6%, accuracy 91.9%, positive predictive values 93.9% and negative predictive values 84.6% in identification of HCC. In evaluation of metastasis MDCT had a sensitivity of 100.0%, specificity 98.3%, accuracy 98.4%, positive predictive values 75.0% and negative predictive values 100.0%. In evaluation of dysplastic nodule MDCT had sensitivity 50.0%, specificity 100.0%, accuracy 98.4%, positive predictive values 100.0% and negative predictive values 98.4%.So, MDCT can be an ideal diagnostic tool for detecting as well as characterizing the hepaticspace occupying lesion (SOLs) in cirrhotic patients.Bangladesh Med Res Counc Bull 2018; 44(1):23-29